(AMPH) Amphastar P - Ratings and Ratios
Enoxaparin, Insulin, Glucagon, Naloxone, Epinephrine
AMPH EPS (Earnings per Share)
AMPH Revenue
Description: AMPH Amphastar P
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a US-based company operating in the Pharmaceuticals sub-industry. The companys market capitalization stands at approximately $1.1 billion, indicating a mid-cap status. With a Return on Equity (ROE) of 19.37%, Amphastar demonstrates a relatively strong ability to generate profits from shareholder equity.
The stocks Price-to-Earnings (P/E) ratio is 8.92, suggesting that the company may be undervalued compared to its earnings. This could be an attractive feature for value investors. However, the forward P/E ratio is not available, potentially due to a lack of analyst estimates or significant variability in earnings forecasts.
Key drivers for Amphastars stock performance may include the companys product portfolio, pipeline developments, and competitive positioning within the pharmaceutical industry. Investors should monitor revenue growth, gross margin trends, and research and development (R&D) expenses to gauge the companys operational performance. Additionally, keeping track of regulatory updates and industry trends will be crucial in assessing Amphastars future prospects.
From a technical perspective, the stocks beta of 0.76 indicates relatively lower volatility compared to the broader market. This, combined with its current price near the 52-week high, suggests that Amphastars stock may be experiencing a degree of stability. Investors should continue to monitor moving averages, such as the SMA20 and SMA50, to identify potential trend reversals or continuations.
AMPH Stock Overview
| Market Cap in USD | 1,366m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-06-25 |
AMPH Stock Ratings
| Growth Rating | -24.2% |
| Fundamental | 77.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -53.2% |
| Analyst Rating | 3.67 of 5 |
AMPH Dividends
Currently no dividends paidAMPH Growth Ratios
| Growth Correlation 3m | 55.9% |
| Growth Correlation 12m | -82.4% |
| Growth Correlation 5y | 58.9% |
| CAGR 5y | -1.21% |
| CAGR/Max DD 3y | -0.02 |
| CAGR/Mean DD 3y | -0.04 |
| Sharpe Ratio 12m | -1.04 |
| Alpha | 0.18 |
| Beta | 0.347 |
| Volatility | 39.87% |
| Current Volume | 920.9k |
| Average Volume 20d | 414.9k |
| Stop Loss | 25.9 (-4%) |
| Signal | -1.08 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (134.7m TTM) > 0 and > 6% of Revenue (6% = 43.2m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -5.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 56.15% (prev 48.49%; Δ 7.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 159.7m > Net Income 134.7m (YES >=105%, WARN >=100%) |
| Net Debt (-139.9m) to EBITDA (248.1m) ratio: -0.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (48.1m) change vs 12m ago -7.53% (target <= -2.0% for YES) |
| Gross Margin 50.03% (prev 53.49%; Δ -3.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 46.37% (prev 47.80%; Δ -1.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.30 (EBITDA TTM 248.1m / Interest Expense TTM 25.7m) >= 6 (WARN >= 3) |
Altman Z'' 4.47
| (A) 0.25 = (Total Current Assets 580.8m - Total Current Liabilities 176.4m) / Total Assets 1.62b |
| (B) 0.39 = Retained Earnings (Balance) 625.1m / Total Assets 1.62b |
| (C) 0.12 = EBIT TTM 187.5m / Avg Total Assets 1.55b |
| (D) 0.72 = Book Value of Equity 619.7m / Total Liabilities 857.9m |
| Total Rating: 4.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.28
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 6.41% = 3.20 |
| 3. FCF Margin 15.58% = 3.89 |
| 4. Debt/Equity 0.81 = 2.18 |
| 5. Debt/Ebitda 2.49 = -0.93 |
| 6. ROIC - WACC (= 6.47)% = 8.08 |
| 7. RoE 18.15% = 1.51 |
| 8. Rev. Trend 80.35% = 6.03 |
| 9. EPS Trend 56.33% = 2.82 |
What is the price of AMPH shares?
Over the past week, the price has changed by -5.00%, over one month by -9.34%, over three months by +5.35% and over the past year by -44.53%.
Is Amphastar P a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMPH is around 22.94 USD . This means that AMPH is currently overvalued and has a potential downside of -14.97%.
Is AMPH a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AMPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.7 | 21.1% |
| Analysts Target Price | 32.7 | 21.1% |
| ValueRay Target Price | 24.9 | -7.9% |
Last update: 2025-09-05 04:32
AMPH Fundamental Data Overview
CCE Cash And Equivalents = 231.8m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 11.0075
P/S = 1.8909
P/B = 1.804
P/EG = 2.77
Beta = 0.76
Revenue TTM = 720.3m USD
EBIT TTM = 187.5m USD
EBITDA TTM = 248.1m USD
Long Term Debt = 607.7m USD (from longTermDebt, last quarter)
Short Term Debt = 8.81m USD (from shortTermDebt, last quarter)
Debt = 616.5m USD (Calculated: Short Term 8.81m + Long Term 607.7m)
Net Debt = -139.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (1.37b + Debt 616.5m - CCE 231.8m)
Interest Coverage Ratio = 7.30 (Ebit TTM 187.5m / Interest Expense TTM 25.7m)
FCF Yield = 6.41% (FCF TTM 112.2m / Enterprise Value 1.75b)
FCF Margin = 15.58% (FCF TTM 112.2m / Revenue TTM 720.3m)
Net Margin = 18.70% (Net Income TTM 134.7m / Revenue TTM 720.3m)
Gross Margin = 50.03% ((Revenue TTM 720.3m - Cost of Revenue TTM 360.0m) / Revenue TTM)
Tobins Q-Ratio = 2.83 (Enterprise Value 1.75b / Book Value Of Equity 619.7m)
Interest Expense / Debt = 1.02% (Interest Expense 6.28m / Debt 616.5m)
Taxrate = 15.64% (29.7m / 189.8m)
NOPAT = 158.2m (EBIT 187.5m * (1 - 15.64%))
Current Ratio = 3.29 (Total Current Assets 580.8m / Total Current Liabilities 176.4m)
Debt / Equity = 0.81 (Debt 616.5m / last Quarter total Stockholder Equity 757.5m)
Debt / EBITDA = 2.49 (Net Debt -139.9m / EBITDA 248.1m)
Debt / FCF = 5.50 (Debt 616.5m / FCF TTM 112.2m)
Total Stockholder Equity = 742.2m (last 4 quarters mean)
RoA = 8.34% (Net Income 134.7m, Total Assets 1.62b )
RoE = 18.15% (Net Income TTM 134.7m / Total Stockholder Equity 742.2m)
RoCE = 13.89% (Ebit 187.5m / (Equity 742.2m + L.T.Debt 607.7m))
RoIC = 11.76% (NOPAT 158.2m / Invested Capital 1.35b)
WACC = 5.30% (E(1.37b)/V(1.98b) * Re(7.30%)) + (D(616.5m)/V(1.98b) * Rd(1.02%) * (1-Tc(0.16)))
Shares Correlation 3-Years: -36.36 | Cagr: -0.84%
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈138.6m ; Y1≈170.9m ; Y5≈291.6m
Fair Price DCF = 106.7 (DCF Value 4.96b / Shares Outstanding 46.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 56.33 | EPS CAGR: 34.01% | SUE: 0.66 | # QB: 0
Revenue Correlation: 80.35 | Revenue CAGR: 14.52% | SUE: N/A | # QB: None
Additional Sources for AMPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle